NCT06340204View on ClinicalTrials.gov

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 25, 2024

Primary Completion Date

March 25, 2026

Study Completion Date

December 25, 2026

Conditions
Ewing Sarcoma
Interventions
DRUG

Irinotecan Hydrochloride Liposome Injection

Irinotecan Hydrochloride Liposome Injection is given weekly by 5 doses every 6 weeks (5/6 qw).

Trial Locations (3)

100034

RECRUITING

Peking University People's Hospital, Beijin

100043

NOT_YET_RECRUITING

Peking University Shougang Hospital, Beijing

250117

NOT_YET_RECRUITING

Shandong Cancer Hospital and Institute, Jina

All Listed Sponsors
collaborator

Peking University Shougang Hospital

OTHER

collaborator

Shandong Cancer Hospital and Institute

OTHER

lead

Peking University People's Hospital

OTHER